Search results for " bet"

showing 4 items of 1744 documents

Excess electronic recoil events in XENON1T

2020

We report results from searches for new physics with low-energy electronic recoil data recorded with the XENON1T detector. With an exposure of 0.65 t-y and an unprecedentedly low background rate of $76\pm2$ events/(t y keV) between 1 and 30 keV, the data enables sensitive searches for solar axions, an enhanced neutrino magnetic moment, and bosonic dark matter. An excess over known backgrounds is observed at low energies and most prominent between 2 and 3 keV. The solar axion model has a 3.4$\sigma$ significance, and a 3D 90% confidence surface is reported for axion couplings to electrons, photons, and nucleons. This surface is inscribed in the cuboid defined by $g_{ae}<3.8 \times 10^{-12}$,…

xenon: targetaxionssolar axionmagnetic momentdimension: 3neutrino: solarPhysics beyond the Standard ModelSolar neutrinodark matter: direct detection01 natural sciences7. Clean energyHigh Energy Physics - ExperimentDark matter direct detection axionHigh Energy Physics - Experiment (hep-ex)neutrinoXENONHigh Energy Physics - Phenomenology (hep-ph)background: lowRecoilelectron: recoil[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]beta-raysParticle Physics Experimentscoupling: (axion 2electron)multi-purpose particle detectornuclear instrumentationComputingMilieux_MISCELLANEOUSinstrumentationPhysicsxenon: liquidboson: dark matteraxion 2nucleontritiumnew physics: search forsemileptonic decayboson: vectortensionneutrino: magnetic momentHigh Energy Physics - Phenomenologyaxion 2photonlow backgroundbosonNeutrinoionizing radiationNucleonAstrophysics - Cosmology and Nongalactic AstrophysicsCosmology and Nongalactic Astrophysics (astro-ph.CO)dark matter detectorelectronic recoilElectron captureXENON1T detectorDark matterlow-energy electronic recoil dataFOS: Physical sciences[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex]dark matterNONuclear physicsPE2_2PE2_1tritium: semileptonic decay0103 physical sciencessolar axion modelsurface[PHYS.PHYS.PHYS-INS-DET]Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det]axion: couplingPE2_4010306 general physicspseudoscalarAxiondark matter: vectordark matter XENON1T detector electronic recoilsolar neutrinodetectorDark Matter Axions Beta Decay Liquid Xenon TPC010308 nuclear & particles physicsaxion 2electroncoupling: (axion 2nucleon)dark matter: detectormodel: axionGran Sassometrology[PHYS.HPHE]Physics [physics]/High Energy Physics - Phenomenology [hep-ph]axionstellar constraintscoupling: (axion 2photon)High Energy Physics::Experimentparticle dark matterdirect detectionbeta decayaxion: solar[PHYS.ASTR]Physics [physics]/Astrophysics [astro-ph]experimental results
researchProduct

Ar tērauda un polipropilēna šķiedrām stiegrota fibrobetona īpašību izpēte

2015

Šajā darbā izpētīta polipropilēna šķiedru ietekme uz parastu un tērauda šķiedrām stiprinātu betonu, veicot četru punktu lieces un vienas šķiedras izvilkšanas eksperimentus. Papildus tika veikta porainības analīze. Iegūtie eksperimentālie rezultāti uzrāda ievērojamu īpašību uzlabošanos tērauda šķiedrām stiprinātam betonam, pievienojot tam polipropilēna šķiedras. Iepriekš veiktos pētījumos nav dots pārliecinošs skaidrojums procesiem, kas atbildīgi par šķiedru sinerģiju. Šī darba autors piedāvā vienkāršu izskaidrojumu mehānismam, kas atbild par paaugstinātām īpašībām tērauda un polipropilēna šķiedrām stiprinātam betonam.

šķiedru betonstrausla matricasinerģijaFizikahibrīds stiprinājums
researchProduct

An arthritogenic alphavirus uses the α1β1 integrin collagen receptor

2005

Ross River (RR) virus is an alphavirus endemic to Australia and New Guinea and is the aetiological agent of epidemic polyarthritis or RR virus disease. Here we provide evidence that RR virus uses the collagen-binding alpha1beta1 integrin as a cellular receptor. Infection could be inhibited by collagen IV and antibodies specific for the beta1 and alpha1 integrin proteins, and fibroblasts from alpha1-integrin-/- mice were less efficiently infected than wild-type fibroblasts. Soluble alpha1beta1 integrin bound immobilized RR virus, and peptides representing the alpha1beta1 integrin binding-site on collagen IV inhibited virus binding to cells. We speculate that two highly conserved regions with…

α1β1 integrinCollagen Type IVIntegrin alpha1IntegrinAlphavirusBiologyVirus ReplicationAntibodiesVirusIntegrin alpha1beta1Collagen receptorMiceRoss River virusVirologyRoss River virusAnimalsHumansMice KnockoutCollagen IVVirus receptorFibroblastsbiology.organism_classificationMolecular biologySolubilityIntegrin alpha Mbiology.proteinReceptors VirusIntegrin beta 6Receptors Adrenergic beta-1ReceptorHeLa CellsVirology
researchProduct

Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 mon…

2014

Summary Background In patients with COPD, exacerbations are associated with poor quality of life and may shorten survival. Prevention of exacerbations is, therefore, a key objective in COPD management. Indacaterol, a once-daily ultra-long-acting β 2 -agonist, has been shown to reduce exacerbations in various studies. This pooled analysis evaluated the effect of indacaterol on exacerbations versus placebo. Methods Six-month data were pooled from three randomized, double-blind, and placebo-controlled studies: indacaterol 300 μg versus placebo (1 year); indacaterol 150 μg and 300 μg versus placebo (6 months); and indacaterol 150 μg versus placebo (6 months). All treatments were administered on…

β2-agonistPulmonary and Respiratory Medicinemedicine.medical_specialtyExacerbationKaplan-Meier EstimateQuinolonesPlaceboDrug Administration SchedulePooled analysisExacerbationsPulmonary Disease Chronic ObstructiveFEV1/FVC ratioDouble-Blind MethodForced Expiratory VolumeInternal medicineHumansCOPDMedicineAdrenergic beta-2 Receptor AgonistsRandomized Controlled Trials as TopicIndacaterolCOPDDose-Response Relationship Drugbusiness.industryMinimal clinically important differenceHazard ratiomedicine.diseaseConfidence intervalBronchodilator AgentsClinical Trials Phase III as TopicAnesthesiaIndansIndacaterolbusinessBronchodilatormedicine.drugRespiratory Medicine
researchProduct